Novikov A I, Zaezzhalkin V V, Kucherov V A, Frolov S Iu
Urologiia. 2010 Jul-Aug(4):44, 46-8.
A total of 55 patients aged 20-59 years with recurrent chronic bacterial prostatitis (RCBP) entered a trial of immunomodulator panavir. The study group consisted of 40 patients. They were given standard treatment and panavir. The control group (n = 15) matched by all the studied characteristics received standard treatment only. Blood count, bacteriological characteristics of prostatic secretion, immunological status, subjective parameters were studied. RCBP patients were diagnosed to have marked disorders of interferon status. The addition of panavir to standard treatment of RCBP patients significantly improved treatment results. Therefore, panavir is recommended as an adjuvant in combined RCBP treatment.
共有55名年龄在20至59岁之间的复发性慢性细菌性前列腺炎（RCBP）患者参与了免疫调节剂泛昔洛韦的试验。研究组由40名患者组成。他们接受了标准治疗和泛昔洛韦治疗。对照组（n = 15）在所有研究特征方面进行匹配，仅接受标准治疗。研究了血细胞计数、前列腺分泌物的细菌学特征、免疫状态和主观参数。RCBP患者被诊断出干扰素状态存在明显紊乱。在RCBP患者的标准治疗中添加泛昔洛韦显著改善了治疗效果。因此，推荐泛昔洛韦作为RCBP联合治疗的辅助药物。
